Codagenix Appoints Linda Maldonado as VP, Biologics Chemistry and Manufacturing Controls
Ms. Maldonado to Oversee Manufacturing Development of Codagenix s Vaccines as Clinical Trials for COVID-19, RSV and Flu Progress
News provided by
Share this article
Share this article
FARMINGDALE, N.Y., April 14, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the appointment of biotech industry veteran Linda Maldonado as Vice President, Biologics Chemistry and Manufacturing Controls (CMC). We are pleased to welcome Linda to Codagenix s growing management team in anticipation of multiple significant growth opportunities this year, including the advancement COVI-VAC, our single-dose, intranasal, live-attenuated COVID-19 vaccine, to late-stage clinical trials, said J. Robert Coleman, Ph.D., CEO of Codagenix. Linda has a proven track record with clinical process development, scale-u
Codagenix Expands Senior Management Team With Three New Appointments
New Hires Bolster Codagenix s Operations, Regulatory Affairs and Clinical Trial Management
News provided by
Share this article
Share this article
NEW YORK, March 17, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appointments. Lisa Runco, Ph.D., has been named Director of Operations. Additionally, Sally Yang, M.S., R.A.C. has been appointed Associate Director of Regulatory Affairs, and Lasmy Tea, M.S., M.P.H., has been named Associate Director of Clinical Project Management.
Share this article
Share this article
NEW YORK, Jan. 26, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the issuance of a patent for a vaccine focused on human codon-deoptimized respiratory syncytial viruses (RSV) vaccine. Codagenix currently holds the exclusive license to this patent. The issuance of US Patent No. 10,695,414 broadens Codagenix s intellectual property portfolio, covering human codon deoptimization of the RSV F and/or G proteins of in a live-attenauted vaccine.
Codagenix is currently investigating its live attenuated CodaVax™-RSV vaccine, an intranasally-administered vaccine for the prevention of RSV, in a randomized, double-blind, placebo-controlled Phase 1 clinical trial. Top line data from trial, which is designed to evaluate the safety, tolerability and immunogenicity of CodaVax
Share this article
Share this article
NEW YORK and PUNE, India, Dec. 14, 2020 /PRNewswire/ Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) today announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK. COVI-VAC is a single-dose intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes COVID-19, that was shown to be safe and efficacious in preclinical animal studies. COVI-VAC was developed with Codagenix s Synthetic Attenuated Virus Engineering (
SAVE) platform that uses synthetic biology to re-code the genes of viruses into safe and stable vaccines. COVI-VAC is designed to deliver a safe, live attenuated version of SARS-CoV-2 that may induce a more robust immune response and long-lasting cellular immunity against SARS-CoV-2 compared to other vaccines against the virus.